When comparing prostate cancer patients (including advanced stages) to patients with benign prostate hyperplasia or early stage prostate cancer, leptin expression was increased, indicating leptin expression can be used as a biomarker for prostate cancer staging and prognosis [284, 285]. The gene discussed is LEP; the disease is benign prostatic hyperplasia.